Search clinical trials for: MMFS-202-302

Total 5331 results

Northwestern University
Brain & Behavior Research Foundation; Neurocentria, Inc.

Completed

Effect of MMFS-202-302 on Cognitive Enhancement in Schizophrenia

Schizophrenia | Schizoaffective Disorder

United States
Bial - Portela C S.A.

Completed

Absorption, Distribution, Metabolism and Excretion of [14C]-Labelled BIA 3-202 and Metabolites

Parkinson's Disease

Switzerland
TScan Therapeutics, Inc.

Recruiting

A Basket Study of Customized Autologous TCR-T Cell Therapies in Patients With Locally Advanced (Unresectable) or Metastatic Solid Tumors

Melanoma | Cervical Cancer | Head and Neck Cancer | HPV-Related Malignancy | Ovarian Cancer | HPV-Related Carcinoma | HPV-Related Cervical Carcinoma | HPV Positive Oropharyngeal Squamous Cell Carcinoma | Non-small Cell Carcinoma | HPV - Anogenital Human Papilloma Virus Infection | HPV-Related Adenocarcinoma | HPV-Related Adenosquamous Carcinoma and other conditions

United States
Hookipa Biotech GmbH

Recruiting

HB-302/HB-301 Therapy in Participants With Metastatic Castration-Resistant Prostate Cancer

Prostate Cancer Metastatic

United States
Evofem Inc.
Neothetics, Inc

Terminated

Extension Study to Evaluate the Post-Treatment Safety and Duration of Clinical Effect of LIPO-202

Central Abdominal Bulging
Hookipa Biotech GmbH

Recruiting

A Phase 1/2 Study in Patients With HPV16+ Recurrent/Metastatic Head and Neck Squamous Cell Carcinoma and Other Cancers

HPV-Related Squamous Cell Carcinoma

United States, Spain, Netherlands
Swiss Tropical & Public Health Institute
Pevion Biotech Ltd; Mymetics Corporation

Completed

Phase Ib Trial of Two Virosome Formulated Malaria Vaccine Components (PEV 301, PEV 302) in Tanzania (PMAL03)

Falciparum Malaria

Tanzania
REGENXBIO Inc.

Recruiting

AFFINITY DUCHENNE: RGX-202 Gene Therapy in Participants With Duchenne Muscular Dystrophy (DMD)

Duchenne Muscular Dystrophy

United States
Alpine Immune Sciences, Inc.

Terminated

An Open-label Study of ALPN-202 in Subjects With Advanced Malignancies (NEON-1)

Lymphoma | Advanced Solid Tumor

United States, Australia
GenSpera, Inc.

Completed

Efficacy, Safety and CNS Exposure of G-202 (Mipsagargin) in Patients With Recurrent or Progressive Glioblastoma

Glioblastoma Multiforme

United States
GenSpera, Inc.

Completed

Dose-Escalation Phase 1 Study of G-202 (Mipsagargin) in Patients With Advanced Solid Tumors

Advanced Solid Tumors

United States
Neothetics, Inc

Unknown

An Open-Label Study to Evaluate Retreatment With LIPO-202

Central Abdominal Bulging

United States
Threshold Pharmaceuticals

Completed

Study of Hypoxia-Activated Prodrug TH-302 to Treat Advanced Leukemias

Acute Lymphoblastic Leukemia | Chronic Lymphocytic Leukemia | Acute Myelogenous Leukemia | Chronic Myelogenous Leukemia | High-risk Myelodysplastic Syndrome | Advanced Myelofibrosis

United States
ILIAS Biologics Inc.

Completed

A Study to Evaluate the Safety and Tolerability of ILB-202

Healthy

Australia
Akron Molecules AG

Completed

A Placebo Controlled, Double Blind, Randomised, 8-week Phase IIa Proof of Concept Study to Assess the Efficacy and Safety of AKR 202 in Patients With Osteoarthritis Pain

Osteoarthritis

Austria
Devalingam Mahalingam
GenSpera, Inc.

No longer available

Continued Administration of G-202 for One Patient With Advanced Hepatocellular Carcinoma

Hepatocellular Carcinoma
GenSpera, Inc.

Withdrawn

Phase 2 Study of G-202 in Patients With Chemotherapy-Naïve Metastatic Castrate-Resistant Prostate Cancer

Prostate Cancer.

United States
Myeloid Therapeutics

Recruiting

Study of MT-302 in Adults With Advanced or Metastatic Epithelial Tumors (MYE Symphony)

Epithelial Tumors, Malignant

Australia
Immune-Onc Therapeutics
California Institute for Regenerative Medicine (CIRM)

Recruiting

IO-202 as Monotherapy and IO-202 Plus Azacitidine ± Venetoclax in Patients in AML and CMML

CMML | AML With Monocytic Differentiation

United States
Oui Therapeutics, Inc.
National Institute of Mental Health (NIMH)

Enrolling by invitation

A Study to Evaluate the Safety and Effectiveness of a Digital Therapeutic

Suicidal Ideation | Suicide, Attempted

United States
Inversago Pharma Inc.

Active, not recruiting

Study of INV-202 in Patients With Obesity and Metabolic Syndrome

Obesity | Metabolic Syndrome

Canada
Inversago Pharma Inc.

Completed

A Study to Explore the PK and PD of INV-202 in Metabolic Syndrome

Metabolic Syndrome

Canada
GenSpera, Inc.

Completed

Safety and Activity of G-202 in Patients With Clear Cell Renal Cell Carcinoma That Expresses PSMA

Clear Cell Renal Cell Carcinoma

United States
GenSpera, Inc.

Completed

G-202 in the Neoadjuvant Setting Followed by Radical Prostatectomy in Patients With Prostate Cancer

Prostatic Neoplasms

United States
GenSpera, Inc.
Saint John's Cancer Institute

Withdrawn

Efficacy and Safety of G-202 in PSMA-Positive Glioblastoma

Glioblastoma

United States
Shanghai Zerun Biotechnology Co.,Ltd
Walvax Biotechnology Co., Ltd.

Active, not recruiting

Phase II Clinical Trial of Recombinant SARS-CoV-2 Spike Protein Vaccine (CHO Cell) for the Prevention of COVID-19

COVID-19

China
Shanghai Zerun Biotechnology Co.,Ltd
Walvax Biotechnology Co., Ltd.

Active, not recruiting

Phase I Clinical Trial of Recombinant SARS-CoV-2 Spike Protein Vaccine (CHO Cell) for the Prevention of COVID-19

COVID-19

China
Avalo Therapeutics, Inc.

Completed

A Study to Evaluate the Safety and Efficacy of AVTX-002 for the Treatment of Poorly Controlled Non-Eosinophilic Asthma.

Non-Eosinophilic Asthma

United States
Neurocentria, Inc.

Completed

Comparison of MMFS Dosages in Older Adults

Depression | Cognitive Impairment | Anxiety | Sleep Quality

United States
Seoul National University Hospital

Completed

NuGa (Nutrition for Gastric Cancer Patients)

Gastric Cancer

Korea, Republic of
Bial - Portela C S.A.

Completed

Safety, Tolerability, Pharmacokinetics (Including Food Interaction), and Pharmacodynamics of BIA 3-202

Parkinson's Disease

United Kingdom
Neothetics, Inc

Completed

A Dose-ranging, Study of the Safety and Efficacy of Subcutaneous Injections of LIPO-102 Compared With Placebo for the Reduction of Abdominal Subcutaneous Adiposity

Weight

United States
Canopy Growth Corporation

Completed

Study to Assess the Safety, Tolerability, and Effects of CHI-202 to Support Recovery From Physical Activity

Delayed Onset Muscle Soreness (DOMS)

United States
Bial - Portela C S.A.

Completed

Study to Investigate the Safety, Tolerability, Steady State Pharmacokinetic and Pharmacodynamic Profile of BIA 3-202

Parkinson's Disease

United Kingdom
Immune-Onc Therapeutics

Active, not recruiting

Dose-Escalation and Dose-Expansion Study of IO-202 and IO-202+Pembrolizumab in Solid Tumors

Solid Tumor, Adult

United States
Inversago Pharma Inc.
Worldwide Clinical Trials

Recruiting

Phase 2 Study of INV-202 in Patients With Diabetic Kidney Disease

Diabetic Kidney Disease

Israel, United States, Mexico, Hungary, Georgia, Serbia, Canada
Bial - Portela C S.A.

Completed

Study to Investigate the Tolerability, Steady-state Pharmacokinetics and Erythrocyte COMT Inhibition of BIA 3-202

Parkinson's Disease

Portugal
Aevi Genomic Medicine, LLC, a Cerecor company

Completed

Clinical Trial to Evaluate CERC-002 in Adults With COVID-19 Pneumonia and Acute Lung Injury

Acute Lung Injury | ARDS | COVID-19 Pneumonia

United States
Vyluma, Inc.
Syneos Health

Active, not recruiting

CHAMP: Study of NVK-002 in Children With Myopia

Myopia

United States, Hungary, Ireland, Netherlands, Spain, United Kingdom
Avalo Therapeutics, Inc.

Terminated

Evaluation of the Safety, Tolerability, and Efficacy of MDGN-002 in Adults With Moderate to Severe Active Crohn's Disease or Ulcerative Colitis

Crohn Disease | Ulcerative Colitis

United States
CinDome Pharma, Inc.

Completed

A Phase 2 Study of CIN-102 in Adults With Idiopathic and Diabetic Gastroparesis

Gastroparesis

United States
9 Meters Biopharma, Inc.

Completed

Safety of Larazotide Acetate in Healthy Volunteers

Healthy

United States
9 Meters Biopharma, Inc.

Completed

Safety Study of Larazotide Acetate to Treat Celiac Disease.

Celiac Disease

United States
9 Meters Biopharma, Inc.

Terminated

Study to Evaluate the Efficacy and Safety of Larazotide Acetate for the Relief of CeD Symptoms

Celiac Disease

United States
4SC AG

Completed

Oral Histone Deacetylase Inhibitor 4SC-202 in Patients With Advanced Hematologic Malignancies (TOPAS)

Advanced Hematologic Malignancies

Germany
Edwards Lifesciences

Recruiting

TRISCEND JAPAN Study (TRISCEND JAPAN)

Cardiovascular Diseases | Heart Valve Diseases | Tricuspid Valve Regurgitation

Japan
Orion Corporation, Orion Pharma

Completed

Safety and Tolerability Study With Single Ascending Doses of ODM-102

Healthy Volunteers

Finland
Arxx Therapeutics

Recruiting

A First in Human Study of AX-202 in Healthy Subjects and Patients With Psoriasis.

Healthy Volunteers | Mild to Moderate Psoriasis

United Kingdom
9 Meters Biopharma, Inc.

Completed

Randomized, Double-Blind, Placebo-Controlled Study of Larazotide Acetate in Subjects With Active Celiac Disease

Celiac Disease

United States, Canada, Spain
9 Meters Biopharma, Inc.
Teva Pharmaceuticals USA

Completed

A Double-blind Placebo-controlled Study to Evaluate Larazotide Acetate for the Treatment of Celiac Disease

Celiac Disease

United States, Canada

Search clinical trials for: MMFS-202-302

Sponsors and Collaborators

Medical Conditions

Drug Interventions

CROs by country

CROs in New Zealand

Conditions

Rare Diseases

Drug Interventions

Dietary Supplements

Sponsor/Collaborators

Locations